Clinical Trial Update: Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of anlotinib and penpulimab as second-line therapy for small cell lung cancer after platinum-based chemotherap…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Penpulimab

Snippet

Sponsor: Hunan Cancer Hospital | Conditions: Small Cell Lung Cancer | Phase 2 | Status: COMPLETED